Allogeneic Hematopoietic Cell Transplantation for AML: is it Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

2015 ◽  
Vol 15 ◽  
pp. S8 ◽  
Author(s):  
Daisuke Araki ◽  
Brent L. Wood ◽  
Megan Othus ◽  
Jerald P. Radich ◽  
Anna B. Halpern ◽  
...  
Keyword(s):  
Complete Remission ◽  
Minimal Residual Disease ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Residual Disease ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Definition Of ◽  
Minimal Residual

scholarly journals How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

Blood ◽  
2020 ◽  
Vol 135 (19) ◽  
pp. 1639-1649 ◽  
Author(s):  
Alexandros Spyridonidis
Keyword(s):  
Acute Leukemia ◽  
Minimal Residual Disease ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Residual Disease ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Leukemia Relapse ◽  
Minimal Residual

Abstract Although allogeneic hematopoietic cell transplantation (allo-HCT) is currently the standard curative treatment of acute leukemia, relapse remains unacceptably high. Measurable (minimal) residual disease (MRD) after allo-HCT may be used as a predictor of impending relapse and should be part of routine follow-up for transplanted patients. Patients with MRD may respond to therapies aiming to unleash or enhance the graft-versus-leukemia effect. However, evidence-based recommendations on how to best implement MRD testing and MRD-directed therapy after allo-HCT are lacking. Here, I describe our institutional approach to MRD monitoring for preemptive MRD-triggered intervention, using patient scenarios to illustrate the discussion.

scholarly journals Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Blood ◽  
2013 ◽  
Vol 122 (10) ◽  
pp. 1813-1821 ◽  
Author(s):  
Roland B. Walter ◽  
Sarah A. Buckley ◽  
John M. Pagel ◽  
Brent L. Wood ◽  
Barry E. Storer ◽  
...  
Keyword(s):  
Complete Remission ◽  
Minimal Residual Disease ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Residual Disease ◽  
Adverse Outcome ◽  
Negative Impact ◽  
Hematopoietic Cell ◽  
Key Points ◽  
Minimal Residual

Key Points The negative impact of pre-HCT flow cytometrically determined MRD is similar for AML in CR1 and CR2. Even minute levels of MRD (≤0.1%) are associated with adverse outcome.

Sign in / Sign up

Export Citation Format

Share Document